Inovio Pharmaceuticals, Inc. (INO) Trades at $4.36 After Triangle; Nuvasive (NUVA) Sentiment Is 1.34

August 10, 2018 - By Tyler Harlow

NuVasive, Inc. (NASDAQ:NUVA) Logo

Inovio Pharmaceuticals, Inc. (INO) formed triangle with $4.62 target or 6.00% above today’s $4.36 share price. Inovio Pharmaceuticals, Inc. (INO) has $398.93M valuation. The stock decreased 2.68% or $0.12 during the last trading session, reaching $4.36. About 1.05 million shares traded or 18.98% up from the average. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 38.67% since August 10, 2017 and is downtrending. It has underperformed by 51.24% the S&P500. Some Historical INO News: 21/05/2018 – Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease; 09/05/2018 – Inovio Pharma 1Q Rev $1.53M; 14/03/2018 – INOVIO 4Q LOSS/SHR 24C, EST. LOSS/SHR 30C; 31/05/2018 – lnovio CEO to Speak on Viral Epidemic Preparedness Panel at BIO International Convention; 11/04/2018 – Inovio Awarded Up to $56 M From CEPI to Advance DNA Vaccines Against Lassa Fever and MERS; 14/03/2018 – INOVIO PHARMACEUTICALS INC INO.O : RBC RAISES TARGET PRICE TO $14 FROM $11; 25/05/2018 – IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase lll Pacific Trial for Unresectable Stage lll Non-Small Cell Lung Cancer; 14/03/2018 – INOVIO’S DNA IMMUNOTHERAPY SHOWS IMMUNE RESPONSE RESULTS KEY IN; 11/04/2018 – INOVIO TO DEVELOP VACCINE CANDIDATES VS LASSA FEVER, MERS; 14/03/2018 – lnovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection

Nuvasive Inc (NUVA) investors sentiment increased to 1.34 in Q1 2018. It’s up 0.43, from 0.91 in 2017Q4. The ratio is better, as 126 active investment managers increased or opened new stock positions, while 94 cut down and sold equity positions in Nuvasive Inc. The active investment managers in our database now own: 51.57 million shares, up from 51.31 million shares in 2017Q4. Also, the number of active investment managers holding Nuvasive Inc in top ten stock positions increased from 1 to 3 for an increase of 2. Sold All: 24 Reduced: 70 Increased: 75 New Position: 51.

Analysts await NuVasive, Inc. (NASDAQ:NUVA) to report earnings on October, 23. They expect $0.63 EPS, up 21.15% or $0.11 from last year’s $0.52 per share. NUVA’s profit will be $32.39M for 25.52 P/E if the $0.63 EPS becomes a reality. After $0.58 actual EPS reported by NuVasive, Inc. for the previous quarter, Wall Street now forecasts 8.62% EPS growth.

The stock increased 2.23% or $1.4 during the last trading session, reaching $64.32. About 242,803 shares traded. NuVasive, Inc. (NUVA) has declined 33.94% since August 10, 2017 and is downtrending. It has underperformed by 46.51% the S&P500. Some Historical NUVA News: 16/05/2018 – NuVasive Sponsors SOLAS 2018, Hosts Workshop On Latest Lateral Innovations; 07/05/2018 – nuvasive, incorporated | nuvasive® xlx interbody system | K173892 | 05/04/2018 |; 01/05/2018 – NuVasive 1Q Loss/Shr 53c; 25/05/2018 – Hartford Healthcare Adds NuVasive, Exits Penumbra; 22/05/2018 – NuVasive PRECICE STRYDE System Used in First Patient for Stature Lengthening by Intl Limb Lengthening Expert; 24/04/2018 – NuVasive Sponsors AANS 2018, Hosts Workshops And Presentations On Latest Innovations; 14/05/2018 – NuVasive Presenting at Bank of America Conference Tomorrow; 22/05/2018 – NuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb Lengthening Expert; 02/04/2018 – NuVasive Portfolio Now Includes ALIF Retractor Platform For Lateral And Supine Approaches; 01/05/2018 – NUVASIVE SEES FY ADJ EPS $2.44 TO $2.47, EST. $2.46

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. The company has market cap of $3.31 billion. The Company’s products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. It has a 77.49 P/E ratio. The companyÂ’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

More recent NuVasive, Inc. (NASDAQ:NUVA) news were published by: Fool.com which released: “Why NuVasive, Inc. Stock Jumped Today” on August 01, 2018. Also Fool.com published the news titled: “Why This Healthcare Innovator Sees a Brighter Future” on August 03, 2018. Seekingalpha.com‘s news article titled: “NuVasive, Inc. 2018 Q2 – Results – Earnings Call Slides” with publication date: July 31, 2018 was also an interesting one.

Consonance Capital Management Lp holds 5.25% of its portfolio in NuVasive, Inc. for 1.10 million shares. Sector Gamma As owns 371,997 shares or 3.5% of their US portfolio. Moreover, Sg Capital Management Llc has 2.52% invested in the company for 251,377 shares. The New York-based Broadfin Capital Llc has invested 2.1% in the stock. Champlain Investment Partners Llc, a Us-based fund reported 3.14 million shares.

Since January 1, 0001, it had 2 buys, and 0 sales for $593,220 activity.

NuVasive, Inc. (NASDAQ:NUVA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts